The National Institutes of Health (NIH) is offering a funding opportunity titled "Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)." This initiative aims to support research focused on identifying targets and pathways to suppress HIV transcription in individuals with comorbid HIV and substance use disorders (SUDs), particularly in the central nervous system. The funding is critical for advancing understanding of how addictive substances influence HIV latency and reactivation, addressing significant health challenges faced by affected populations. Applications for this grant are due by August 14, 2024, with a total funding pool of $2 million expected to support four to six projects. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.